GENOVIS RIGHTS ISSUE 91% SUBSCRIBED

The preliminary outcome of Genovis’ rights issue is a subscription rate of about 91%. Existing shareholders subscribed to 67 % of the total proceeds from the share issue. The rights issue raised about SEK 18 million before issue expenses for Genovis. Statements of account are expected to be sent on May 13 2011, to allot shares subscribed without preferential rights.

For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46 46 10 12 35 sarah.fredriksson@genovis.com

Genovis develops and designs smart nanoparticles for preclinical imaging and diagnostics and also develops and sells tools for modification of antibodies.Genovis shares are listed on Nasdaq OMX First North and Thenberg & Kinde Fondkommission ( 46 (0)31 745 50 00) is the Company’s certified adviser.